Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease

Inclusion Criteria: * Age ≥18 years. * Diagnosis of Crohn's disease with colonic or perianal involvement confirmed by endoscopic, histologic and/or radiologic data. * CDAI score ≥200 and ≤400. Exclusion Criteria: * Subjects known to have stool positive for Clostridium difficile toxin A or B, bacterial enteric pathogens, rotavirus, Cryptosporidium species (spp.), and/or ova/parasites. * Evidence of bowel obstruction. * Females that are pregnant, breast-feeding or not using birth control and are sexually active. * Serious systemic disorders incompatible with the study. * History of hypersensitivity to nitazoxanide or any inactive ingredient in the formulation. * Uncontrolled gastro-intestinal bleeding. * Evidence of intestinal abscess, non-perianal fistula or stricture. * Patients who have received antibiotics in the past 7 days. * Patients receiving \>20 mg of prednisone, or its equivalent. * Patients receiving Anucort-HC or rectal steroids. * Patients receiving immunosuppressive therapy that has not been stabilized. * Patients who have received TNF-alpha inhibitor treatments such as infliximab or other biological agents within three months prior to start of treatment. * Patients with Crohn's disease confined to the esophagus, stomach and small bowel.